VEGFA and neoplasm: In a review of breast cancer patients, an overwhelming 81% of 37 clinical studies demonstrated that the VEGF level in tumor or serum, as determined by either immunohistochemistry or ELISA method, serves as an adverse prognostic marker for disease-free or overall survival [2].